Skip to main content
Top
Published in: Clinical and Experimental Medicine 1/2011

01-03-2011 | Original Article

Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia

Authors: Pan-pan Cheng, Xiao-yang Jiao, Xue-hua Wang, Jing-hua Lin, Ying-mu Cai

Published in: Clinical and Experimental Medicine | Issue 1/2011

Login to get access

Abstract

Hepcidin is a key hormone governing mammalian iron homeostasis and may be directly or indirectly involved in the development of most iron deficiency/overload and inflammation-induced anemia. The objective of this study was to investigate the expression of hepcidin in anemia of chronic disease. To characterize serum hepcidin, iron and inflammatory indicators associated with anemia of chronic disease (ACD), we studied ACD, ACD concomitant iron-deficiency anemia (ACD/IDA), pure IDA and acute inflammation (AcI) patients and analyzed the associations between hepcidin levels and inflammation parameters in various types of anemia. Serum hepcidin levels in patient groups were statistically different, from high to low: ACD, AcI > ACD/IDA > the control > IDA. Serum ferritin levels were significantly increased in ACD and AcI patients but were decreased significantly in ACD/IDA and IDA. Elevated serum EPO concentrations were found in ACD, ACD/IDA and IDA patients but not in AcI patients and the controls. A positive correlation between hepcidin and IL-6 levels only existed in ACD/IDA, AcI and the control groups. A positive correlation between hepcidin and ferritin was marked in the control group, while a negative correlation between hepcidin and ferritin was noted in IDA. The significant negative correlation between hepcidin expression and reticulocyte count was marked in both ACD/IDA and IDA groups. All of these data demonstrated that hepcidin might play role in pathogenesis of ACD, ACD/IDA and IDA, and it could be a potential marker for detection and differentiation of these anemias.
Literature
1.
3.
4.
go back to reference Brugnara C (2003) Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 49:1573–1578CrossRefPubMed Brugnara C (2003) Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 49:1573–1578CrossRefPubMed
5.
go back to reference Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066–1076PubMed Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066–1076PubMed
6.
go back to reference Metzgeroth G, Adelberger V, Dorn-Beineke A, Kuhn C, Schatz M, Maywald O, Bertsch T, Wisser H, Hehlmann R, Hastka J (2005) Soluble transferrin receptor and zinc protoporphyrin—competitors or efficient partners? Eur J Haematol 75:309–317CrossRefPubMed Metzgeroth G, Adelberger V, Dorn-Beineke A, Kuhn C, Schatz M, Maywald O, Bertsch T, Wisser H, Hehlmann R, Hastka J (2005) Soluble transferrin receptor and zinc protoporphyrin—competitors or efficient partners? Eur J Haematol 75:309–317CrossRefPubMed
7.
go back to reference Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100:3776–3781CrossRefPubMed Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100:3776–3781CrossRefPubMed
8.
go back to reference Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271–1276PubMed Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271–1276PubMed
9.
go back to reference Nemeth E, Ganz T (2006) Hepcidin and iron-loading anemias. Haematologica 91:727–732PubMed Nemeth E, Ganz T (2006) Hepcidin and iron-loading anemias. Haematologica 91:727–732PubMed
10.
go back to reference Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093CrossRefPubMed Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093CrossRefPubMed
11.
go back to reference Kemna EH, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93:90–97CrossRefPubMed Kemna EH, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93:90–97CrossRefPubMed
12.
go back to reference Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007) Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53:620–628CrossRefPubMed Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007) Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53:620–628CrossRefPubMed
13.
go back to reference Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type ii acute-phase protein. Blood 101:2461–2463CrossRefPubMed Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type ii acute-phase protein. Blood 101:2461–2463CrossRefPubMed
14.
go back to reference Piperno A, Mariani R, Trombini P, Girelli D (2009) Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol 15:538–551CrossRefPubMed Piperno A, Mariani R, Trombini P, Girelli D (2009) Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol 15:538–551CrossRefPubMed
15.
go back to reference Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ, Wurz E, Datz C, Weiss G (2009) Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113:5277–5286CrossRefPubMed Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ, Wurz E, Datz C, Weiss G (2009) Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113:5277–5286CrossRefPubMed
16.
go back to reference Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68:215–223CrossRefPubMed Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68:215–223CrossRefPubMed
17.
go back to reference Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783–788CrossRefPubMed Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783–788CrossRefPubMed
18.
go back to reference Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99:4596–4601CrossRefPubMed Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99:4596–4601CrossRefPubMed
19.
go back to reference Beutler E (2007) Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 39:140–147CrossRefPubMed Beutler E (2007) Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 39:140–147CrossRefPubMed
20.
go back to reference Lee GR (1983) The anemia of chronic disease. Semin Hematol 20:61–80PubMed Lee GR (1983) The anemia of chronic disease. Semin Hematol 20:61–80PubMed
21.
go back to reference Dallalio G, Law E, Means RT Jr (2006) Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107:2702–2704CrossRefPubMed Dallalio G, Law E, Means RT Jr (2006) Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107:2702–2704CrossRefPubMed
22.
go back to reference Fleming RE (2008) Iron and inflammation: cross-talk between pathways regulating hepcidin. J Mol Med 86:491–494CrossRefPubMed Fleming RE (2008) Iron and inflammation: cross-talk between pathways regulating hepcidin. J Mol Med 86:491–494CrossRefPubMed
23.
go back to reference Ganz T (2006) Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 46:554–557CrossRefPubMed Ganz T (2006) Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 46:554–557CrossRefPubMed
24.
go back to reference De Domenico I, Ward DM, Kaplan J (2007) Hepcidin regulation: ironing out the details. J Clin Invest 117:1755–1758CrossRefPubMed De Domenico I, Ward DM, Kaplan J (2007) Hepcidin regulation: ironing out the details. J Clin Invest 117:1755–1758CrossRefPubMed
25.
go back to reference Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D (2005) Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with lps. Blood 106:1864–1866CrossRefPubMed Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D (2005) Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with lps. Blood 106:1864–1866CrossRefPubMed
26.
go back to reference Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G (2006) Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 107:4142–4148CrossRefPubMed Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G (2006) Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 107:4142–4148CrossRefPubMed
27.
go back to reference Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976–981CrossRefPubMed Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976–981CrossRefPubMed
28.
go back to reference Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037–1044PubMed Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037–1044PubMed
29.
go back to reference Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006) Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108:3730–3735CrossRefPubMed Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006) Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108:3730–3735CrossRefPubMed
30.
go back to reference Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 92:583–588CrossRefPubMed Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 92:583–588CrossRefPubMed
31.
go back to reference Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91:809–812PubMed Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91:809–812PubMed
32.
go back to reference Vokurka M, Krijt J, Sulc K, Necas E (2006) Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 55:667–674PubMed Vokurka M, Krijt J, Sulc K, Necas E (2006) Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 55:667–674PubMed
33.
go back to reference Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T (2008) Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 93:1550–1554CrossRefPubMed Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T (2008) Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 93:1550–1554CrossRefPubMed
35.
go back to reference Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G (2008) Erythropoietin mediates hepcidin expression in hepatocytes through epor signaling and regulation of c/ebpalpha. Blood 111:5727–5733CrossRefPubMed Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G (2008) Erythropoietin mediates hepcidin expression in hepatocytes through epor signaling and regulation of c/ebpalpha. Blood 111:5727–5733CrossRefPubMed
Metadata
Title
Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia
Authors
Pan-pan Cheng
Xiao-yang Jiao
Xue-hua Wang
Jing-hua Lin
Ying-mu Cai
Publication date
01-03-2011
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 1/2011
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0102-9

Other articles of this Issue 1/2011

Clinical and Experimental Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine